Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial
Ravassa, S.; Trippel, T.; Bach, D.; Bachran, D.; González, A.; López, B. & Wachter, R. et al. (2018)
European Journal of Heart Failure, 20(9) pp. 1290-1299. DOI: https://doi.org/10.1002/ejhf.1194
Documents & Media
Details
- Title Variant(s)
- Myocardial fibrosis and effect of spironolactone in HFpEF
- Authors
- Ravassa, Susana; Trippel, Tobias; Bach, Doris; Bachran, Diana; González, Arantxa; López, Begoña; Wachter, Rolf ; Hasenfuss, Gerd ; Delles, Christian; Dominiczak, Anna F.; Pieske, Burkert ; Díez, Javier; Edelmann, Frank
- Issue Date
- 2018
- Journal
- European Journal of Heart Failure
- ISSN
- 1388-9842
- Language
- English
